Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells
Version of Record online: 28 OCT 2013
© 2013 Japanese Cancer Association
Volume 104, Issue 12, pages 1618–1625, December 2013
How to Cite
(Cancer Sci 2013; 104: 1618–1625)
- Issue online: 6 DEC 2013
- Version of Record online: 28 OCT 2013
- Accepted manuscript online: 24 SEP 2013 07:05AM EST
- Manuscript Accepted: 19 SEP 2013
- Manuscript Revised: 11 SEP 2013
- Manuscript Received: 2 JUL 2013
Fig. S1. Other inhibitors cannot block HRG1-mediated phosphorylation of HER3 and AKT.
Fig. S2. Other inhibitors cannot abrogate HRG1-mediated resistance.
Fig. S3. Trastuzumab cannot inhibit HRG1-mediated phosphorylation of HER3 and AKT and HRG1-mediated resistance to lapatinib.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.